| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | NMDAR2B, hNR3, MGC142180, glutamate receptor subunit epsilon-2, NR3 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Fusion protein amino acids 20-271 (extracellular N-terminus) of rat NR2B |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
NR2B (GRIN2B) is a subunit of the NMDA receptor complex, predominantly expressed during early brain development and in specific regions of the adult brain such as the hippocampus and cortex. NR2B-containing NMDA receptors exhibit slower deactivation kinetics and higher calcium permeability, making them critical for synaptic plasticity, memory formation, and neurodevelopment.
In neurodegenerative disease research, NR2B has been implicated in excitotoxicity, a pathological process driven by excessive glutamate signaling and calcium influx. Overactivation of NR2B-containing receptors contributes to neuronal injury in conditions such as Alzheimer’s disease, Parkinson’s disease, and stroke.
Pharmacological modulation of NR2B has shown promise in preclinical models for reducing neurotoxicity and improving cognitive function. NR2B-selective antagonists are being explored as therapeutic agents for neuroprotection and symptom management in neurodegenerative and neuropsychiatric disorders. Its developmental regulation and synaptic specificity make NR2B a valuable target for precision neuroscience.
1 µg/ml of SMC-337 was sufficient for detection of NR2B in 10 µg of rat brain lysate by colorimetric immunoblot analysis using goat anti-mouse IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SMC-337D — Size: 100 ug: GluN2B Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-337D, RRID: AB_2294803)
- SMC-337D-A390 — Size: 100 ug: GluN2B Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-337D-A390, RRID: AB_2700601)
- SMC-337D-A488 — Size: 100 ug: GluN2B Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-337D-A488, RRID: AB_2700602)
- SMC-337D-A594 — Size: 100 ug: GluN2B Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-337D-A594, RRID: AB_2700604)
- SMC-337D-APC — Size: 100 ug: GluN2B Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-337D-APC, RRID: AB_2700610)
- SMC-337D-BI — Size: 100 ug: GluN2B Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-337D-BI, RRID: AB_2700611)
- SMC-337D-FITC — Size: 100 ug: GluN2B Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-337D-FITC, RRID: AB_2700612)
- SMC-337D-HRP — Size: 100 ug: GluN2B Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-337D-HRP, RRID: AB_2700613)
- SMC-337D-PCP — Size: 100 ug: GluN2B Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-337D-PCP, RRID: AB_2700615)
- SMC-337D-RPE — Size: 100 ug: GluN2B Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-337D-RPE, RRID: AB_2700616)
- SMC-337S — Size: 12 ug: GluN2B Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-337S, RRID: AB_2294803)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Gurwitz D, and Weizman A. (2002) Drug Discovery Today, 7(7): 403-406.